Additionally, DPP4 inhibitors may protect against the progression of cognitive disorders in diabetic individuals by increasing neurotrophin levels, such as BDNF, NGF, and NT-4 [57], promoting neuronal growth, survival, and synaptic plasticity. The gene discussed is BDNF; the disease is cognitive disorder.